Literature DB >> 11713616

The selective serotonin reuptake inhibitor paroxetine is effective in more generalized and in less generalized social anxiety disorder.

D J Stein1, M B Stein, W Goodwin, R Kumar, B Hunter.   

Abstract

RATIONALE: The DSM-IV includes the specifier "generalized" to refer to social anxiety disorder (social phobia) patients if the fears include "most social situations". The focus on interventions such as the selective serotonin reuptake inhibitors (SSRIs) for generalized social anxiety disorder arguably runs the risk that inadequate treatment will be provided to patients with the non-generalized or discrete subtypes. There are, however, few data to address whether more generalized and less generalized subgroups of social anxiety disorder differ in response to medication.
OBJECTIVE: To compare response of more generalized and less generalized social anxiety disorder to pharmacotherapy.
METHODS: Data from three randomized placebo-controlled double-blind multicenter trials of the SSRI paroxetine in social anxiety disorder were pooled. Response on the Clinical Global Impression Global Improvement item was analyzed using logistic regression, and change in total Liebowitz Social Anxiety Score was analyzed using analysis of variance, with both models incorporating treatment (paroxetine vs placebo), subgroup (more generalized vs less generalized), demographic, and clinical variables.
RESULTS: The prevalence of more generalized social anxiety disorder was higher in females than in males. However, there was no significant difference in terms of age or clinical characteristics (duration of condition, baseline pulse, mean arterial blood pressure). At treatment endpoint there were significant treatment effects (for paroxetine vs placebo), but no significant subgroup effects (for more generalized vs less generalized).
CONCLUSIONS: Although the current database is limited insofar as few patients with discrete social anxiety disorder would have been included, it is helpful in addressing the value of medication for patients lying on the spectrum from generalized to non-generalized and discrete social anxiety disorder. Paroxetine was effective in both more generalized and in less generalized social anxiety disorder.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11713616     DOI: 10.1007/s002130100880

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  8 in total

1.  A 2010 evidence-based algorithm for the pharmacotherapy of social anxiety disorder.

Authors:  Dan J Stein; David S Baldwin; Borwin Bandelow; Carlos Blanco; Leonardo F Fontenelle; Sing Lee; Hisato Matsunaga; David Osser; Murray B Stein; Michael van Ameringen
Journal:  Curr Psychiatry Rep       Date:  2010-10       Impact factor: 5.285

Review 2.  Social anxiety disorder : current treatment recommendations.

Authors:  Jacqueline E Muller; Liezl Koen; Soraya Seedat; Dan J Stein
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 3.  Predictors of pharmacotherapy response in anxiety disorders.

Authors:  Damiaan Denys; Femke de Geus
Journal:  Curr Psychiatry Rep       Date:  2005-08       Impact factor: 5.285

Review 4.  Recent Insight Into the Subtypes of Social Anxiety Disorder.

Authors:  Catherine D'Avanzato; Kristy L Dalrymple
Journal:  Curr Psychiatry Rep       Date:  2016-05       Impact factor: 5.285

5.  Benzodiazepines: more "behavioural" addiction than dependence.

Authors:  Carlos de las Cuevas; Emilio Sanz; Juan de la Fuente
Journal:  Psychopharmacology (Berl)       Date:  2003-04-01       Impact factor: 4.530

6.  Subtyping social anxiety disorder in developed and developing countries.

Authors:  Dan J Stein; Ayelet Meron Ruscio; Sing Lee; Maria Petukhova; Jordi Alonso; Laura Helena S G Andrade; Corina Benjet; Evelyn Bromet; Koen Demyttenaere; Silvia Florescu; Giovanni de Girolamo; Ron de Graaf; Oye Gureje; Yanling He; Hristo Hinkov; Chiyi Hu; Noboru Iwata; Elie G Karam; Jean-Pierre Lepine; Herbert Matschinger; Mark Oakley Browne; Jose Posada-Villa; Rajesh Sagar; David R Williams; Ronald C Kessler
Journal:  Depress Anxiety       Date:  2010-04       Impact factor: 6.505

7.  Psychopharmacology of anxiety disorders.

Authors:  Giovanni B Cassano; Nicolò Baldini Rossi; Stefano Pini
Journal:  Dialogues Clin Neurosci       Date:  2002-09       Impact factor: 5.986

8.  Initial severity and antidepressant efficacy for anxiety disorders, obsessive-compulsive disorder, and posttraumatic stress disorder: An individual patient data meta-analysis.

Authors:  Ymkje Anna de Vries; Annelieke M Roest; Johannes G M Burgerhof; Peter de Jonge
Journal:  Depress Anxiety       Date:  2018-04-16       Impact factor: 6.505

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.